Clinical and pharmacodynamic (PD) results of a phase I trial with AMP-224 (B7-DC Fc) that binds to the PD-1 receptor.
Jeffrey R. Infante
No relevant relationships to disclose
John D. Powderly
Employment or Leadership Position - Biolytics Pharma
Consultant or Advisory Role - Amplimmune; Bristol-Myers Squibb; Genentech/Roche
Stock Ownership - Biolytics Pharma
Honoraria - Bristol-Myers Squibb; Genentech/Roche
Research Funding - Amgen; Amplimmune; Celldex; Genentech/Roche; ImClone Systems; Lilly; Millennium
Other Remuneration - Biolytics Pharma
Howard A. Burris
No relevant relationships to disclose
Muaiad Kittaneh
No relevant relationships to disclose
Jessica Houston Grice
No relevant relationships to disclose
James F Smothers
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Research Funding - GlaxoSmithKline
Other Remuneration - Amplimmune
Sara Brett
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Research Funding - GlaxoSmithKline
Other Remuneration - Amplimmune
Margaret E. Fleming
Employment or Leadership Position - Amplimmune
Stock Ownership - Amplimmune
Rena May
Employment or Leadership Position - Amplimmune
Stock Ownership - Amplimmune
Shannon Marshall
Employment or Leadership Position - Amplimmune
Stock Ownership - Amplimmune
Martin Devenport
Employment or Leadership Position - Amplimmune
Stock Ownership - Amplimmune
Stanley Pillemer
Consultant or Advisory Role - Amplimmune
Stock Ownership - Amplimmune
Drew M. Pardoll
Consultant or Advisory Role - Amplimmune (U)
Lieping Chen
Consultant or Advisory Role - Amplimmune
Stock Ownership - Amplimmune
Research Funding - Amplimmune
Solomon Langermann
Employment or Leadership Position - Amplimmune
Stock Ownership - Amplimmune
Patricia LoRusso
Research Funding - Amplimmune